Core Viewpoint - Mural Oncology (MURA) announced the discontinuation of all clinical development of nemvaleukin alfa, leading to a 134% surge in its stock price as investors anticipate potential strategic alternatives to maximize shareholder value [1][3]. Company Decisions - The company will explore various strategic options, including a potential sale, merger, or other transactions, with no set timeline for this process [2]. - Mural Oncology will reduce its workforce by 90% as part of its restructuring efforts [1]. Financial Performance - As of December 31, 2024, Mural Oncology reported approximately $144.4 million in cash, cash equivalents, and marketable securities [4]. Pipeline Setbacks - The decision to halt clinical development follows the failure of the phase II ARTISTRY-6 study for melanoma and disappointing results from the phase III ARTISTRY-7 study for platinum-resistant ovarian cancer (PROC) [4][9]. - The ARTISTRY-6 study did not meet its primary goal, and the ARTISTRY-7 study showed no statistically significant improvement in overall survival compared to chemotherapy [7][9]. Market Reaction - Investors reacted positively to the announcement, likely due to hopes of recovering value lost from previous setbacks, as MURA shares have declined 25.2% year-to-date compared to the industry’s 7.1% decline [3].

Core Viewpoint - Tempest Therapeutics, Inc. is exploring strategic options to enhance stockholder value, which may include mergers, acquisitions, partnerships, or licensing arrangements [1] Company Development Plans - Tempest is developing amezalpat (TPST-1120), a PPAR-alpha antagonist, for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) [2] - The company is also working on TPST-1495, a selective EP2-EP4 dual antagonist, for treating familial adenomatous polyposis (FAP) [2] - Tempest has partnered with Roche to evaluate amezalpat in combination with Roche's Tecentriq and Avastin for HCC treatment [5] - The FDA has cleared Tempest to begin a pivotal phase III study for amezalpat in combination with Roche's therapy for HCC [6] - Ongoing studies have shown that amezalpat combined with Roche's therapy resulted in a six-month improvement in median overall survival compared to the standard therapy alone [7] - The FDA has granted Fast Track and Orphan Drug designations to amezalpat for HCC treatment [7] - Tempest has received a "Study May Proceed" letter from the FDA for a phase II study on TPST-1495, expected to start in 2025 [9] - The FDA has also granted Orphan Drug designation to TPST-1495 for FAP treatment [9] - Management believes that amezalpat has blockbuster potential in HCC, while TPST-1495 also shows promise [10] Stock Performance - Following the announcement of strategic options, Tempest's shares rose by 6.3% in after-hours trading on April 9 [2] - Year-to-date, Tempest's shares have decreased by 34.1%, compared to a 14.6% decline in the industry [3]

Financial Data and Key Metrics Changes - Revenues for Q4 2024 were $2.0 million, an increase of $0.3 million or 13% compared to the same period in the prior year, driven by higher digital game sales from the release of Le Mans Ultimate [27] - Net loss for Q4 2024 was $2.9 million, a decrease of $5.6 million compared to net income of $2.7 million for the same period in the prior year [28] - Full year 2024 revenues were $8.7 million, up $1.8 million compared to the prior year, primarily due to $3.0 million in digital game and downloadable content sales [30] - Net loss for 2024 was $3.0 million, an improvement from $14.3 million in 2023 [30] - Adjusted EBITDA loss for 2024 was $3.9 million, an improvement from $9.3 million in 2023 [31] - Net cash used in operations for the year ended December 31, 2024, was approximately $3.2 million, with an average monthly cash burn of $0.3 million, down from $1.1 million in 2023 [32] Business Line Data and Key Metrics Changes - The launch of Le Mans Ultimate in February 2024 significantly contributed to revenue growth, with digital game sales being a primary driver [30] - The introduction of downloadable content (DLC) such as the 2024 Pack 3, which included popular car models and tracks, has boosted sales and player engagement [21] Market Data and Key Metrics Changes - The subscription service launched in December generated over $120,000 in gross revenues within the first 21 days, indicating strong early adoption [18] - The company reported nearly 6,000 active subscribers, showcasing potential for long-term monetization [19] Company Strategy and Development Direction - The company is focused on improving product quality while balancing aggressive cost reductions, aiming to reconnect with players and enhance brand perception [9][12] - Future opportunities include exploring console ports for PlayStation and Xbox, contingent on proving success on the PC platform [17] - The company is actively exploring additional funding options and strategic alternatives, including potential equity and debt financing [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's turnaround, emphasizing the importance of respect in the sim racing industry and the positive momentum gained from recent successes [36] - The company is optimistic about future growth opportunities, particularly in the underserved racing market [16] Other Important Information - A settlement with Luminis improved the company's financial position by $180,000 and cleared barriers to full ownership of Studio 397 [24] - A positive ruling in litigation with Innovate Corporation may alleviate some legal fee liabilities, enhancing stockholders' equity [25] Summary of Q&A Session - There were no questions during the Q&A session, and the call concluded without any formal inquiries [38]

Core Viewpoint - CarParts.com is exploring strategic alternatives, including a potential sale, after receiving inbound inquiries, with no set timeline for completion and no certainty of a strategic change [1][2] Company Performance - In the third quarter, CarParts.com reported a 13% decline in net sales year-over-year, totaling $144.8 million, alongside a net loss of $10 million [3] - The sales decrease was attributed to deliberate price increases aimed at higher value customers, gross margin expansion, and challenges in the consumer environment, as well as one-time impacts from external events [4] Strategic Initiatives - The company has invested significantly in building a vertically integrated supply chain and a nationwide fulfillment network to enhance its eCommerce experience and mobile app [3] - CarParts.com is undergoing a re-platforming process to improve performance and reduce development cycles, with expectations to capitalize on opportunities in the $400 billion auto parts market [5] User Engagement - The cumulative downloads of CarParts.com's mobile app have more than doubled to over 550,000 at the beginning of the year, indicating growing user engagement despite sales challenges [4]

As filed with the U.S. Securities and Exchange Commission on July 19, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 180 Life Sciences Corp. (Exact name of registrant as specified in its charter) Delaware 2834 90-1890354 Interim Chief Executive Officer 180 Life Sciences Corp. 3000 El Camino Real, Bldg. 4, Suite 200 Palo Alto, CA 94306 (650) 507-0669 (State or other jurisdiction of (Primary Standard Industrial (I.R ...